Gilbert Syndrome in Pregnancy

Background

How Pregnancy Interacts with Gilbert Syndrome

Physiological Changes That Affect Bilirubin in Pregnancy

• Hemodilution of pregnancy (expanded plasma volume) tends to lower baseline bilirubin, which can actually mask Gilbert syndrome or normalize previously elevated levels.
• Increased red cell turnover (especially in late pregnancy and postpartum) can increase bilirubin load.
• Fasting, nausea/vomiting (common in the first trimester) is a well-known trigger for Gilbert flares — serum bilirubin can rise significantly during hyperemesis gravidarum.
• Labor and delivery stress, fasting during labor, and the physical exertion of delivery are classic triggers.

Triggers to Watch for in Pregnancy

Diagnosis / Distinguishing from Pathological Jaundice

• Gilbert syndrome = isolated unconjugated hyperbilirubinemia with normal liver enzymes (ALT, AST, ALP, GGT), normal CBC, and normal bile acids.
• If bilirubin is conjugated (direct), Gilbert syndrome is NOT the explanation — investigate further.
• A personal and/or family history of episodic mild jaundice since childhood, worsened by fasting, supports the diagnosis.

Management During Pregnancy

General Principles

Practical Management Steps

1. Reassure the patient — Gilbert syndrome is benign and does not cause liver damage, cirrhosis, or increased maternal/fetal mortality.
2. Avoid known triggers:
   • Encourage adequate caloric intake, especially in the first trimester.
   • Manage hyperemesis gravidarum aggressively with antiemetics and IV fluids if needed to prevent prolonged fasting.
   • Avoid unnecessary fasting periods (e.g., prolonged NPO before elective procedures).
3. Monitor liver function — Obtain a baseline LFT panel (ALT, AST, ALP, GGT, total + direct bilirubin, bile acids) early in pregnancy. Repeat if bilirubin rises or symptoms develop, primarily to rule out co-existing or emergent pathology.
4. Drug interactions to consider (Harrison's, p. 1930):
   • Irinotecan: reduced UGT1A1 activity leads to toxicity (diarrhea, myelosuppression) — avoid or use with caution if chemotherapy is needed.
   • Atazanavir (antiretroviral): inhibits UGT1A1, raising bilirubin further — clinically benign but may create diagnostic confusion if the patient is on HAART for HIV.
   • These interactions are rarely relevant in routine obstetric practice but matter in co-morbid patients.
5. Neonatal considerations:
   • Neonates born to mothers with Gilbert syndrome may themselves carry the UGT1A1 variant (autosomal recessive with incomplete penetrance) and may have prolonged or more pronounced neonatal jaundice.
   • Inform the neonatology/pediatric team.
   • No specific intervention is required prenatally, but awareness facilitates prompt neonatal bilirubin monitoring.

Prognosis

• Maternal: Excellent. Gilbert syndrome does not progress to liver disease. It does not increase the risk of pregnancy complications in isolation.
• Fetal/Neonatal: No increased risk of fetal harm. Unconjugated bilirubin does not cross the placenta in harmful amounts because the placenta efficiently transfers bilirubin to the maternal circulation for conjugation and excretion.
• The main clinical risk is misdiagnosis — attributing a new pathological cause of jaundice to Gilbert syndrome and delaying workup.

Summary